Association between Low Serum Magnesium Level and Major Adverse Cardiac Events in Patients Treated with Drug-Eluting Stents for Acute Myocardial Infarction
Objectives We investigated the association of serum magnesium (Mg) levels and major adverse cardiac events (MACEs) after drug-eluting stent (DES) implantation. Background Mg depletion plays a key role in the pathphysiologic features of diabetes mellitus, hypertension, thrombosis, arrhythmias and coronary artery disease. Whether the depletion is related to the long-term prognosis of DES implantation is not known. Methods From 2008 to 2011, we enrolled 414 consecutive patients <50 years old who underwent DES implantation for acute coronary syndrome. Serum Mg level was analyzed and patients were followed up for a median of 24 months (interquartile range 14–32 months) for the occurrence of MACEs defined as death, myocardial infarction, stroke, and any revascularization. Results For patients with unstable angina, no significant association between serum Mg level and MACEs was found in the multivariate model. For patients with myocardial infarction, after adjusting for age, positive family history, smoking status, hypertension, hypercholesterolemia, and diabetes at baseline, the risk was 8.11-fold higher for patients with quartile 1 than 4 Mg level (95% confidence interval 1.7–38.75; P<0.01). In addition, when tested as a continuous variable, serum magnesium was a significant predictor for MACEs of acute myocardial infarction (HR [per 0.1 mM increase], 0.35 [95% CI, 0.19–0.63], p< 0.01), after adjustment for other confounders. Conclusions Low serum level of Mg may be an important predictor of MACEs with DES implantation for acute myocardial infarction. Further research into the effectiveness of Mg supplementation for these patients is warranted.
References
[1]
Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, et al. (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119: 3198–3206. doi: 10.1161/circulationaha.108.826479
[2]
Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, et al. (2009) Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 122: 581 e581–510.
[3]
Ishikawa K, Aoyama Y, Hirayama H (2012) Management of drug-eluting stent restenosis. J Invasive Cardiol 24: 178–182.
[4]
Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, et al. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115: 1051–1058. doi: 10.1161/circulationaha.106.675934
[5]
Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, et al. (2002) Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem 238: 163–179. doi: 10.1023/a:1019998702946
[6]
Gartside PS, Glueck CJ (1995) The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr 14: 71–79. doi: 10.1080/07315724.1995.10718476
[7]
Ford ES (1999) Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 28: 645–651. doi: 10.1093/ije/28.4.645
[8]
Reffelmann T, Ittermann T, Dorr M, Volzke H, Reinthaler M, et al. (2011) Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 219: 280–284. doi: 10.1016/j.atherosclerosis.2011.05.038
[9]
Dasgupta A, Sarma D, Saikia UK (2012) Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab 16: 1000–1003. doi: 10.4103/2230-8210.103020
[10]
Lima Mde L, Cruz T, Rodrigues LE, Bomfim O, Melo J, et al. (2009) Serum and intracellular magnesium deficiency in patients with metabolic syndrome–evidences for its relation to insulin resistance. Diabetes Res Clin Pract 83: 257–262. doi: 10.1016/j.diabres.2008.11.019
[11]
Qin SY, Zhou Y, Jiang HX, Hu BL, Tao L, et al. (2013) The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One 8: e72710. doi: 10.1371/journal.pone.0072710
[12]
Cojocaru IM, Cojocaru M, Burcin C, Atanasiu NA (2007) Serum magnesium in patients with acute ischemic stroke. Rom J Intern Med 45: 269–273.
[13]
Shechter M, Merz CN, Rude RK, Paul Labrador MJ, Meisel SR, et al. (2000) Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am Heart J 140: 212–218. doi: 10.1067/mhj.2000.107553
[14]
Roth A, Eshchar Y, Keren G, Kerbel S, Harsat A, et al. (1994) Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population. A pilot study. The Ichilov Magnesium Study Group. Eur Heart J 15: 1164–1173.
[15]
Pereira JN, Rabacal C, Laires MJ, Pereira T, Fernandes JS, et al. (1988) Serum and red blood cell Mg levels in acute coronary events. Magnesium 7: 9–15.
[16]
Rasmussen HS, Aurup P, Hojberg S, Jensen EK, McNair P (1986) Magnesium and acute myocardial infarction. Transient hypomagnesemia not induced by renal magnesium loss in patients with acute myocardial infarction. Arch Intern Med 146: 872–874. doi: 10.1001/archinte.1986.00360170068010
[17]
Pollak A, Rokach A, Blumenfeld A, Rosen LJ, Resnik L, et al. (2004) Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease. Eur Heart J 25: 240–245. doi: 10.1016/j.ehj.2003.10.028
[18]
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, et al. (2012) Third universal definition of myocardial infarction. Circulation 126: 2020–2035. doi: 10.1161/cir.0b013e31826e1058
[19]
Shivakumar K (2001) Model of cardiovascular injury in magnesium deficiency. Med Hypotheses 56: 110–113. doi: 10.1054/mehy.2000.1123
[20]
Sherer Y, Bitzur R, Cohen H, Shaish A, Varon D, et al. (2001) Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 14: 173–179.
[21]
Dong JY, Xun P, He K, Qin LQ (2011) Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 34: 2116–2122. doi: 10.2337/dc11-0518
[22]
Morrill GA, Gupta RK, Kostellow AB, Ma GY, Zhang A, et al. (1997) Mg2+ modulates membrane lipids in vascular smooth muscle: a link to atherogenesis. FEBS Lett 408: 191–194. doi: 10.1016/s0014-5793(97)00420-1
[23]
Fiset C, Kargacin ME, Kondo CS, Lester WM, Duff HJ (1996) Hypomagnesemia: characterization of a model of sudden cardiac death. J Am Coll Cardiol 27: 1771–1776. doi: 10.1016/0735-1097(96)00089-7
[24]
Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, et al. (2013) Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 127: 33–38. doi: 10.1161/circulationaha.111.082511
[25]
Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, et al. (2010) Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 160: 464–470. doi: 10.1016/j.ahj.2010.06.012
[26]
Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, et al. (2000) Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 102: 2353–2358. doi: 10.1161/01.cir.102.19.2353
[27]
Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M, et al. (2004) Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke 35: 22–27. doi: 10.1161/01.str.0000105928.95124.1f
[28]
Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, et al. (1999) Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol 84: 152–156. doi: 10.1016/s0002-9149(99)00225-8
[29]
Ravn HB, Kristensen SD, Vissinger H, Husted SE (1996) Magnesium inhibits human platelets. Blood Coagul Fibrinolysis 7: 241–244. doi: 10.1097/00001721-199603000-00033
[30]
Sternberg K, Gratz M, Koeck K, Mostertz J, Begunk R, et al. (2012) Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. J Biomed Mater Res B Appl Biomater 100: 41–50. doi: 10.1002/jbm.b.31918
